JP2017536414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536414A5 JP2017536414A5 JP2017545861A JP2017545861A JP2017536414A5 JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5 JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- acid sequence
- amino acid
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000001210 retinal vessel Anatomy 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US62/084,003 | 2014-11-25 | ||
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US62/147,232 | 2015-04-14 | ||
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
| US14/943,490 | 2015-11-17 | ||
| PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Division JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536414A JP2017536414A (ja) | 2017-12-07 |
| JP2017536414A5 true JP2017536414A5 (enExample) | 2018-12-27 |
Family
ID=56009149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545861A Pending JP2017536414A (ja) | 2014-11-25 | 2015-11-19 | 血管性眼疾患を処置するための方法および製剤 |
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1861116T1 (sl) | 2005-03-25 | 2015-12-31 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonistov VEGF |
| MY150400A (en) | 2006-04-07 | 2014-01-15 | Aerpio Therapeutics Inc | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| WO2014127479A1 (en) | 2013-02-21 | 2014-08-28 | Rsem, Limited Partnership | Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| CA2981021C (en) * | 2015-03-26 | 2020-11-17 | Eyekor, Llc | Image analysis |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| US20190300607A1 (en) * | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
| IL270267B2 (en) * | 2017-05-06 | 2024-06-01 | Regeneron Pharma | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
| WO2019036604A1 (en) * | 2017-08-18 | 2019-02-21 | Regeneron Pharmaceuticals, Inc. | IMAGE CAPILLARY ISOELECTRIC FOCUSING FOR ANALYSIS OF PROTEIN VARIANTS IN A SAMPLING MATRIX |
| MX2020005166A (es) * | 2017-11-30 | 2020-09-03 | Regeneron Pharma | Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. |
| JP7692699B2 (ja) * | 2017-12-22 | 2025-06-16 | サムスン バイオエピス カンパニー リミテッド | Ｖｅｇｆアンタゴニストを含む液体組成物 |
| IL310376B1 (en) | 2018-01-26 | 2025-10-01 | Univ California | Methods and compositions for treating angiogenic disorders using anti-VEGF factors |
| CN119909169A (zh) * | 2018-02-06 | 2025-05-02 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US11667702B2 (en) | 2018-03-08 | 2023-06-06 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| AU2019265005B2 (en) | 2018-05-10 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CN112912104A (zh) * | 2018-08-17 | 2021-06-04 | 三钰生物科技股份有限公司 | 抗血管新生融合蛋白及其用途 |
| BR112021007946A2 (pt) | 2018-10-29 | 2021-08-03 | F. Hoffmann-La Roche Ag | formulação de anticorpo |
| CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| AR117707A1 (es) | 2018-12-18 | 2021-08-25 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
| CN113474360B (zh) | 2019-02-18 | 2025-01-07 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ， インコーポレイテッド | シュレム管を標的とするＴｉｅ－２活性化物質 |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| WO2021220138A1 (en) * | 2020-04-29 | 2021-11-04 | Novartis Ag | A computer-implemented system and method for assessing a level of activity of a disease or condition in a patient's eye |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN115734971A (zh) * | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| JP2023535933A (ja) * | 2020-07-24 | 2023-08-22 | パンジェン バイオテック インコーポレイテッド | 眼科用液状組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| SI2364691T1 (sl) * | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| EP2435075A2 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| MX349901B (es) * | 2011-01-13 | 2017-08-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. |
| US9402898B2 (en) * | 2012-01-23 | 2016-08-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| RS62509B1 (sr) * | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| HRP20210517T1 (hr) * | 2012-12-05 | 2021-05-14 | Novartis Ag | Pripravci i postupci za protutijela usmjerena na epo |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JP2016523956A (ja) * | 2013-07-11 | 2016-08-12 | ノバルティス アーゲー | 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| DE112014005747T5 (de) * | 2013-12-17 | 2016-10-06 | Kymab Limited | Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536414A5 (enExample) | ||
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| JP6367233B2 (ja) | 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用 | |
| US9926369B2 (en) | Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody | |
| CA2870338C (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| CN104258390B (zh) | 针对人血管生成素‑2的高亲和力人抗体 | |
| JP2020114218A5 (enExample) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2016504416A5 (enExample) | ||
| JP2014532072A5 (enExample) | ||
| US9932397B2 (en) | VEGFA/Ang2 Compounds | |
| US20160152717A1 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP2021507677A5 (enExample) | ||
| JP6002354B1 (ja) | Ａｎｇ２抗体 | |
| US20240425574A1 (en) | Anti-pdgf-b antibodies and pharmaceutical composition thereof | |
| KR20130133274A (ko) | Tgf-알파 및 에피레굴린에 결합하는 항체 | |
| JP2020518641A5 (enExample) | ||
| TWI859339B (zh) | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| EP4519317A1 (en) | Multispecific binding molecules and methods of use thereof | |
| RU2021125763A (ru) | Биспецифическое антитело, специфически связывающееся с vegf и ang2 | |
| EA049293B1 (ru) | АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| JPWO2023132547A5 (enExample) |